
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc has recently bolstered its financial foundation by closing a $57.5 million public offering, which will support its ongoing clinical programs and extend its financing runway. The company's Phase 1/2 ‘extreme-dose’ trials have demonstrated strong safety profiles, instilling high confidence in the long-term use of its antibody candidates, ADG20 and VYD222. With the upcoming REVOLUTION launch dictating a positive regulatory and commercial narrative, Invivyd is positioned favorably in the market, preparing for pivotal trials that could enhance its competitive edge in addressing viral diseases.
Bears say
The negative outlook on Invivyd Inc.'s stock is primarily driven by a revision of market expectations for its product PEMGARDA, particularly concerning its potential share in the immunocompromised patient sector, resulting in a significant price target reduction. Additionally, dilution from recent capital raises has further weakened the company’s financial position, raising concerns about its ability to compete effectively in the antibody-based treatment space. While Invivyd aims to address limitations in current vaccines through engineered immunity, the challenges of achieving meaningful market penetration amid existing vaccine reluctance and competition still loom large, threatening the company's revenue prospects.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares